Published in Cancer Res on September 15, 2004
Antitumor immunity and cancer stem cells. Ann N Y Acad Sci (2009) 1.36
Immune escape mechanisms of intraocular tumors. Prog Retin Eye Res (2009) 1.07
Prevalence of heterotypic tumor/immune cell-in-cell structure in vitro and in vivo leading to formation of aneuploidy. PLoS One (2013) 1.05
Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res (2014) 0.99
Influence of immune privilege on ocular tumor development. Ocul Immunol Inflamm (2010) 0.97
Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nat Rev Clin Oncol (2016) 0.91
Onto better TRAILs for cancer treatment. Cell Death Differ (2016) 0.88
Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system. World J Gastroenterol (2005) 0.88
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology (2015) 0.88
Dual treatment with COX-2 inhibitor and sodium arsenite leads to induction of surface Fas Ligand expression and Fas-Ligand-mediated apoptosis in human melanoma cells. Exp Cell Res (2006) 0.87
Palmitoylation of human FasL modulates its cell death-inducing function. Cell Death Dis (2010) 0.82
Increased levels of soluble CD226 in sera accompanied by decreased membrane CD226 expression on peripheral blood mononuclear cells from cancer patients. BMC Immunol (2009) 0.81
P2X7 signaling promotes microsphere embolism-triggered microglia activation by maintaining elevation of Fas ligand. J Neuroinflammation (2012) 0.78
Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity? Curr Pharmacogenomics Person Med (2010) 0.77
Presence and phenotype of dendritic cells in uveal melanoma. Br J Ophthalmol (2007) 0.77
Clinical significance of Fas and FasL protein expression in gastric carcinoma and local lymph node tissues. World J Gastroenterol (2010) 0.76
Significance of Fas and FasL protein expression in cardiac carcinoma and local lymph node tissues. Int J Clin Exp Pathol (2015) 0.76
Immune oppression array elucidating immune escape and survival mechanisms in uveal melanoma. Int J Ophthalmol (2016) 0.75
Ocular diseases: immunological and molecular mechanisms. Int J Ophthalmol (2016) 0.75
Heat-shock proteins as activators of the innate immune system. Trends Immunol (2002) 2.96
Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res (2010) 2.74
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Circulating heat shock protein and heat shock protein antibody levels in established hypertension. J Hypertens (2002) 2.05
Regulatory T cells in cancer. Adv Cancer Res (2010) 2.02
Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood (2008) 1.96
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. 1986. J Immunol (2005) 1.64
A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog (2007) 1.56
DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res (2007) 1.45
Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity? J Immunother (2011) 1.44
Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol (2009) 1.38
Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother (2011) 1.36
On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol (2012) 1.35
Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J Leukoc Biol (2007) 1.28
The Haemophilus ducreyi cytolethal distending toxin activates sensors of DNA damage and repair complexes in proliferating and non-proliferating cells. Cell Microbiol (2002) 1.26
IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest (2002) 1.24
The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood (2011) 1.24
A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci U S A (2006) 1.22
Regulation of expression of Bcl-2 protein family member Bim by T cell receptor triggering. Proc Natl Acad Sci U S A (2004) 1.20
Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res (2002) 1.18
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A (2008) 1.18
Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer (2004) 1.17
Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res (2013) 1.17
Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol (2003) 1.17
Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. Blood (2010) 1.14
Is survivin the potential Achilles' heel of cancer? Adv Cancer Res (2011) 1.12
HLA expression in uveal melanoma: there is no rule without some exception. Hum Immunol (2002) 1.08
Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X(L). Cancer Immunol Immunother (2002) 1.05
Detection of human perforin by ELISpot and ELISA: ex vivo identification of virus-specific cells. J Immunol Methods (2005) 1.04
T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer (2010) 1.03
A structural basis for LCMV immune evasion: subversion of H-2D(b) and H-2K(b) presentation of gp33 revealed by comparative crystal structure.Analyses. Immunity (2002) 1.02
Functional gap junctions facilitate melanoma antigen transfer and cross-presentation between human dendritic cells. J Immunol (2007) 1.01
The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica (2006) 1.01
Capacity of Epstein-Barr virus to infect monocytes and inhibit their development into dendritic cells is affected by the cell type supporting virus replication. J Gen Virol (2004) 1.01
HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. J Immunol (2012) 1.00
HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother (2008) 1.00
Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress. J Immunol (2008) 0.98
Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer (2010) 0.98
Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res (2013) 0.97
Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. Cancer Res (2006) 0.97
Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines. Int J Cancer (2011) 0.97
Immunization with heat shock protein 70 from methylcholanthrene-induced sarcomas induces tumor protection correlating with in vitro T cell responses. Cancer Immunol Immunother (2002) 0.97
A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res (2005) 0.97
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med (2010) 0.97
The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol (2013) 0.96
Expression and prognostic significance of iNOS in uveal melanoma. Int J Cancer (2010) 0.96
Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J Immunother (2005) 0.94
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma. Cancer Immunol Immunother (2008) 0.94
Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation. Stem Cells (2013) 0.93
Oxidative stress and lymphocyte persistence: implications in immunotherapy. Adv Cancer Res (2009) 0.93
Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. Oncoimmunology (2012) 0.93
From binding motifs in ChIP-Seq data to improved models of transcription factor binding sites. J Bioinform Comput Biol (2013) 0.93
Tumor-dependent increase of serum amino acid levels in breast cancer patients has diagnostic potential and correlates with molecular tumor subtypes. J Transl Med (2013) 0.92
Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA. Prostate (2005) 0.92
DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity. Mol Ther (2010) 0.91
The CD16- CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subset. J Immunol (2007) 0.91
A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and Transporter associated with Antigen Processing 1/2 in human melanoma cells. J Immunol (2004) 0.90
CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer (2004) 0.90
Syntaxin 11 marks a distinct intracellular compartment recruited to the immunological synapse of NK cells to colocalize with cytotoxic granules. J Cell Mol Med (2012) 0.89
Marked enhancement of the antigen-specific immune response by combining plasmid DNA-based immunization with a Schiff base-forming drug. Infect Immun (2002) 0.89
Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunol Immunother (2009) 0.89
A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunol Immunother (2014) 0.88
Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy. Invest Ophthalmol Vis Sci (2007) 0.88
Inhibition of heavy chain and beta2-microglobulin synthesis as a mechanism of major histocompatibility complex class I downregulation during Epstein-Barr virus replication. J Virol (2006) 0.88
Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J Immunol (2008) 0.88
The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes. Oncoimmunology (2013) 0.87
Mature dendritic cells induce tumor-specific type 1 regulatory T cells. J Immunother (2005) 0.86
Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes. Cancer Res (2003) 0.86
Deficiency of a Niemann-Pick, type C1-related protein in toxoplasma is associated with multiple lipidoses and increased pathogenicity. PLoS Pathog (2011) 0.85
Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors. Cancer Res (2010) 0.85
IFN-gamma regulates Fas ligand expression in human CD4+ T lymphocytes and controls their anti-mycobacterial cytotoxic functions. Eur J Immunol (2007) 0.85
Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues. J Immunol (2004) 0.85
Comparative expression profiling of distinct T cell subsets undergoing oxidative stress. PLoS One (2012) 0.85
T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production. Int Immunol (2006) 0.85
A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer. Clin Cancer Res (2002) 0.84
HER-2/neu-mediated down-regulation of biglycan associated with altered growth properties. J Biol Chem (2012) 0.84
Priming of CD8+ T-cell responses after DNA immunization is impaired in TLR9- and MyD88-deficient mice. Vaccine (2007) 0.83
Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients. Oncoimmunology (2012) 0.82
Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother (2012) 0.82
Nuclear HER3 is associated with favorable overall survival in uveal melanoma. Int J Cancer (2011) 0.82
HLA-dependent tumour development: a role for tumour associate macrophages? J Transl Med (2013) 0.82
Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells. Cancer Immunol Immunother (2005) 0.81
Differentiation induced by physiological and pharmacological stimuli leads to increased antigenicity of human neuroblastoma cells. Cell Res (2008) 0.81